Pfizer Reported Positive Results for Asthma Drug Trial
The company has announced that its experimental drug, tilrekimig, met its primary endpoints in a Phase 2 trial.
Updated on Oct. 1, 2026 in Asthma
Live Poll
Do you trust that major pharmaceutical firms are effectively planning for their long-term financial future?
Pfizer announced positive Phase 2 clinical trial results for its investigational drug tilrekimig. The treatment demonstrated significant efficacy in patients with moderate-to-severe atopic dermatitis during monthly-dosing stages.
Why it matters
Pfizer is moving to advance the drug into Phase 3 trials for both atopic dermatitis and asthma to diversify its revenue beyond COVID-era products. The company aims to address chronic inflammatory conditions through this novel trispecific antibody.
In the Phase 2 trial, 47.8% to 61.0% of patients achieved EASI-75 during the monthly-dosing stage compared to 9.1% on placebo. The investigational drug, which features an extended half-life of 37 days, was also tested at a 450mg dose.
The players
Pfizer
Pfizer is a multinational pharmaceutical and biotechnology corporation headquartered in the United States.
The details
Tilrekimig is a trispecific antibody designed to block IL-4, IL-13, and TSLP via once-monthly injections. The randomized, blinded study successfully met its primary endpoint for patients with moderate-to-severe atopic dermatitis.
Timeline
Pfizer reported diluted earnings of 47 cents per share in Q1 2026.
The company recorded a net loss of $248 million in Q2 2026.
Six company executives filed Form 4 documents on September 29, 2026.
The trial results were announced on October 1, 2026.
Phase 3 asthma trial results are expected in 2027 at the earliest.
The Big Picture
This development follows the trajectory of the ongoing Phase 2b/3 study for COPD as the company attempts to expand its respiratory health portfolio.
Patients with moderate-to-severe atopic dermatitis may eventually have access to a new treatment requiring only once-monthly injections. This development potentially offers a more convenient dosing schedule for those managing chronic inflammatory conditions.
The takeaway
The successful Phase 2 results for tilrekimig underscore a significant shift in Pfizer's drug pipeline as it pursues new multi-target therapies. Patients managing chronic skin and respiratory conditions should watch for future Phase 3 updates as this treatment moves toward potential clinical use.
What happens next
Pfizer intends to proceed with Phase 3 clinical trials for both atopic dermatitis and asthma, with results for the asthma trials anticipated in 2027.
Further reading
Learn more about advancements in respiratory medicine on the Asthma page.
More information
View the Phase 2 dermatitis trial registration for detailed study specifications.
Live Poll
Do you trust that major pharmaceutical firms are effectively planning for their long-term financial future?
